ClinicalTrials.gg
TerminatedNCT02687542Updated Nov 23, 2020Results posted

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

A Phase 2 interventional study of Placebo and PF-06649751 low dose (1 mg QD) in Parkinson Disease, sponsored by Pfizer. Terminated at 57 sites in 6 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-11-23.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
Terminated 25Sep17 due to insufficient efficacy. Not due to safety reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.

Enrollment
5th of 11
108 · median 57
Started
2016
with 1 other
Phase 2
2 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
4 of 11
Pfizer

Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is one of 2 in phase 2, and was the 3rd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About tavapadon

tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing tavapadon in Parkinson Disease as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.

Read the detailed description

The study has a randomized, double-blind, placebo-controlled parallel group design. Approximately 198 subjects will be randomized to 5 treatment groups. Each subject will participate in the study for approximately 23 weeks including a 30 day screening period, 15 week double blind treatment period, and an approximately 28 day follow-up period.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson Disease
  • Motor Fluctuation
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females of non- and/or male subjects between the ages of 40 and 85 years, inclusive.
  • Clinical diagnosis of Parkinson's disease.
  • Able to refrain from any Parkinson's disease medication not permitted by the protocol.

Exclusion criteria

Exclusion Criteria:

  • Female of
  • History or presence of atypical Parkinsonian syndrome.
  • History of surgical intervention for Parkinson's disease.
  • Severe acute or chronic medical or psychiatric condition or laboratory abnormality.
  • Any condition possibly affecting drug absorption.
  • Participation in other studies involving drug(s), or treatment with any investigational drug within 30 days.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
108 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    PF-06649751 low dose (1 mg QD)

    PF-06649751 low dose level (1 mg QD)

    Drug: PF-06649751 low dose (1 mg QD)

  • Experimental
    PF-06649751 middle dose 1 (3 mg QD)

    PF-06649751 lower middle dose 1 (3 mg QD)

    Drug: PF-06649751 middle dose 1 (3 mg QD)

  • Experimental
    PF-06649751 middle dose 2 (7 mg QD)

    PF-06649751 higher middle dose 2 (7 mg QD)

    Drug: PF-06649751 middle dose 2 (7 mg QD)

  • Experimental
    PF-06649751 high dose (15 mg QD)

    PF-06649751 high dose (15 mg QD)

    Drug: PF-06649751 high dose (15 mg QD)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Daily OFF Time at Week 10

    A paper Hauser diary was utilized to record motor state for half-hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization). The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit.

    Time frame: Week 10; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).

Secondary outcomes

  1. Change From Baseline in Daily OFF Time

    A paper Hauser diary was utilized to record motor state for half hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization). The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.

    Time frame: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).

  2. Change From Baseline in Daily ON Time With Troublesome Dyskinesia

    A paper Hauser diary was utilized to record motor state for half hour intervals. The participants answered the Hauser diary on whether they had been ON with troublesome dyskinesia. A diary day started with the interval 24:00-0:30 through 23:30-24:00 on each chronological day for 3 consecutive days. On the days recording the home diary, participants made an entry every 30 minutes during their normal waking time and upon awakening from time asleep. The daily ON hours was calculated as the average of the 3 consecutive daily ON hours from the Hauser diary at each visit. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.

    Time frame: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily ON time with Troublesome Dyskinesia (using 3 Hauser patient diary Days) prior to Day -1 (study derived day and equalled to nominal visit Day 0).

  3. Change From Baseline in Daily ON Time Without Troublesome Dyskinesia

    A paper Hauser diary was utilized to record motor state for half hour intervals. The participants answered the Hauser diary on whether they had been ON without troublesome dyskinesia. A diary day started with the interval 24:00-0:30 through 23:30-24:00 on each chronological day for 3 consecutive days. On the days recording the home diary, participants made an entry every 30 minutes during their normal waking time and upon awakening from time asleep. The daily ON hours was calculated as the average of the 3 consecutive daily ON hours from the Hauser diary at each visit. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.

    Time frame: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily ON time without Troublesome Dyskinesia (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit Day 0)

  4. Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III

    MDS-UPDRS Part III assessed the motor signs of Parkinson's disease and was administered by the investigator. It was comprised of 33 sub-scores based on 18 items, several with right, left or other body distribution scores. Each question was anchored with 5 responses that were linked to commonly accepted clinical terms: 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. If more than 7 of the Part III items were missing, the score for that time point was missing, otherwise MDS-UPDRS Part III score was imputed as sum of the non-missing items\*(total number of items)/ (number of items non-missing). The MDS-UPDRS Part III total score range is 0-132. Higher score indicated more severe motor signs of Parkinson's disease. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.

    Time frame: Weeks 1, 2, 3, 4, 5, 10 and 15; Baseline was defined as the Day -1 (study derived day and equalled to nominal visit Day 0) measurement

  5. Change From Baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, IV, and Total Score

    Each question of Part I,II or IV with 5 responses was linked to the same clinical terms as Part III.The score was missing if more than 7 items were missing for a time point; otherwise Part I,II or IV score was imputed as sum of non-missing items\*(total number of items)/(number of items non-missing).•PartI (Non-Motor Aspects of Experiences of Daily Living) assessed non-motor experiences of daily living using 13questions(Range:0-52).•PartII(Motor Aspects of Experiences of Daily Living) assessed motor experiences of daily living using 13questions(Range:0-52).•PartIV(Motor Complications) assessed motor complications,dyskinesias, and motor fluctuations using historical and objective information with 6questions(Range:0-24).•MDS-UPDRS Total Score:the sum of Parts I,II,III,and IV(Range:0-260).Higher score indicated more severe motor signs of Parkinson's disease.Week15's results were interpreted cautiously given almost half participants were not available for the analysis as compared to Week10

    Time frame: Weeks 5, 10 and 15; Baseline was defined as the Day -1 (study derived day and equalled to nominal visit Day 0) measurement

  6. Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality

    The safety laboratory tests including Hematology, Clinical Chemistry and Urinalysis were performed. Determination if there were any laboratory data abnormalities of potential clinical concern was based on Pfizer Data Standards. Incidence of laboratory test abnormalities (without regard to baseline abnormality) was summarized within each treatment group.

    Time frame: Baseline (Day 0) to Week 17

  7. Number of Participants With Vital Sign Results Meeting the Criteria for Categorical Summarization

    Vital Signs including blood pressure and pulse rate were measured. Vital signs were collected first while the participant was in the supine position and then in the standing position.

    Time frame: Baseline (Day 0) to Week 17

  8. Number of Participants With Electrocardiogram (ECG) Results Meeting the Criteria for Categorical Summarization

    The average of the triplicate readings of ECG data was collected at each assessment time. Number of participants with ECG results meeting the criteria for categorical summarization for time from the beginning of the P wave until the beginning of the QRS complex (PR Interval), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS Duration), time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT Interval) and corrected QT (Fridericia correction) (QTcF Interval) were presented.

    Time frame: Baseline (Day 0) to Week 17

  9. Number of Participants With Suicidal Ideation Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS) at Post-baseline Visits

    The Columbia Suicide Severity Rating Scale (C-SSRS) was an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS responses were mapped to the C-CASA. There were 3 key endpoints for suicidality data analysis and evaluation: * Suicidal Behavior: A participant was said to have suicidal behavior if the participant had experienced completed suicide / suicide attempt / reparatory acts toward imminent suicidal behavior. * Suicidal Ideation: Any observed suicidal ideation mapped to a single C-CASA category. * Suicidal Behavior or Ideation (participants with new onset suicidality): A participant was considered to have a new onset of suicidality if the participant reported no ideation and no behavior at the baseline assessment and reported any behavior or ideation post-baseline. Data observed at screening was not considered in the definition of worsening.

    Time frame: Days 0 (Baseline), 7, 14, 21, 28, 35, 70, 77, 84, 91, 105 and 119

  10. Change From Baseline in Total Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)

    The QUIP-RS was a brief, patient reported outcome measure designed to assess the severity of symptoms of Impulsive-Compulsive Disorders (ICDs) and related behaviors reported to occur in Parkinson's disease. The QUIP-RS assessed 7 disorders (Gambling, Sex, Buying, Eating, Hobbyism-punding \[performing tasks and repeating activities\] and Taking medications). If more than 5 items were missing, the total QUIP-RS score was set as missing; otherwise, the total QUIP-RS score was imputed as follows: sum of the non-missing item scores \* (total number of items) / (number of items non-missing). The higher score indicated a greater level of the ICD. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112.

    Time frame: Baseline (Day 0) and Weeks 5, 10 and 15

  11. Total Physician Withdrawal Checklist (PWC-20) on Days 105 and 119, and Change From Day 105 to Day 119

    The PWC-20 is a physician completed, 20 item reliable and sensitive instrument for the assessment of discontinuation symptoms. The PWC-20 was collected after the completion of study treatment and also at the first visit of follow-up. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. If more than 5 items were missing, the total PWC-20 score was missing; otherwise, the total PWC-20 score was imputed as follows: sum of the non-missing items \* (total number of items) / (number of items non-missing). The higher score indicated more frequent/severe symptoms.

    Time frame: Days 105 and 119

  12. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths

    An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event did not need necessarily to have a causal relationship with the treatment or usage. An SAE was any untoward medical occurrence at any dose that: * Resulted in death; * Was life threatening (immediate risk of death); * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); * Resulted in congenital anomaly/birth defect.

    Time frame: Day 1 to follow-up (Week 19 visit)

07

Results

Posted Dec 24, 2018
Limitations and caveats
The study was terminated prematurely due to insufficient efficacy and not due to safety reasons.

Participant flow

Participant flow — Overall Study
MilestonePlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
Started2313151344
Completed1511324
Not completed812141020
Withdrew: Medication error without associated aes00001
Withdrew: Lost to follow-up00001
Withdrew: Protocol violation01000
Withdrew: Other591065
Withdrew: Adverse event31329
Withdrew: Withdrawal by subject01124

Outcome measures

PrimaryChange From Baseline in Daily OFF Time at Week 10

A paper Hauser diary was utilized to record motor state for half-hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization). The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit.

Time frame:
Week 10; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).
Reported as:
Least squares mean · Hours
Change From Baseline in Daily OFF Time at Week 10
HoursPlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
Change From Baseline in Daily OFF Time at Week 10-0.969 ± 0.4092-1.173 ± 0.3482-1.316 ± 0.3289-1.480 ± 0.3460-1.663 ± 0.4297
Statistical analysis
  • Placebo vs PF-06649751 15 mg QD · Bayesian Dose Response Analysis · p = 0.5776 (Bayesian Predictive Test for Emax (the additive increase over Placebo in the response of PF-06649751 at a theoretically infinite dose) Monotonicity) · Bayesian dose reponse estimate: -0.693 · 90% CI -1.713 to 0.304Estimate and 90% credible interval of Bayesian dose response difference from placebo
SecondaryChange From Baseline in Daily OFF Time

A paper Hauser diary was utilized to record motor state for half hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization). The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.

Time frame:
Weeks 3, 5, 10 and 15; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).
Reported as:
Least squares mean · Hours
Change From Baseline in Daily OFF Time
HoursPlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
Change at Week 3-0.67 ± 0.620-0.82 ± 1.237-0.55 ± 1.091-1.82 ± 1.182-1.01 ± 0.464
Change at Week 5-0.63 ± 0.490-2.04 ± 1.054-2.23 ± 0.964-1.41 ± 0.937-1.24 ± 0.392
Change at Week 10-0.99 ± 0.628-0.60 ± 1.423-1.00 ± 1.508-2.07 ± 1.187-1.63 ± 0.502
Change at Week 151.05 ± 1.063-0.67 ± 2.960-2.75 ± 2.936-1.09 ± 1.687-2.47 ± 0.793
SecondaryChange From Baseline in Daily ON Time With Troublesome Dyskinesia

A paper Hauser diary was utilized to record motor state for half hour intervals. The participants answered the Hauser diary on whether they had been ON with troublesome dyskinesia. A diary day started with the interval 24:00-0:30 through 23:30-24:00 on each chronological day for 3 consecutive days. On the days recording the home diary, participants made an entry every 30 minutes during their normal waking time and upon awakening from time asleep. The daily ON hours was calculated as the average of the 3 consecutive daily ON hours from the Hauser diary at each visit. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.

Time frame:
Weeks 3, 5, 10 and 15; Baseline was defined as the average daily ON time with Troublesome Dyskinesia (using 3 Hauser patient diary Days) prior to Day -1 (study derived day and equalled to nominal visit Day 0).
Reported as:
Least squares mean · Hours
Change From Baseline in Daily ON Time With Troublesome Dyskinesia
HoursPlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
Change at Week 30.17 ± 0.2360.07 ± 0.4670.19 ± 0.4170.01 ± 0.4640.23 ± 0.179
Change at Week 50.23 ± 0.198-0.21 ± 0.415-0.02 ± 0.3880.45 ± 0.3630.03 ± 0.162
Change at Week 100.13 ± 0.1910.24 ± 0.4640.32 ± 0.529-0.39 ± 0.3890.13 ± 0.167
Change at Week 150.01 ± 0.642-0.43 ± 1.349-0.29 ± 1.2630.54 ± 1.071-0.21 ± 0.463
SecondaryChange From Baseline in Daily ON Time Without Troublesome Dyskinesia

A paper Hauser diary was utilized to record motor state for half hour intervals. The participants answered the Hauser diary on whether they had been ON without troublesome dyskinesia. A diary day started with the interval 24:00-0:30 through 23:30-24:00 on each chronological day for 3 consecutive days. On the days recording the home diary, participants made an entry every 30 minutes during their normal waking time and upon awakening from time asleep. The daily ON hours was calculated as the average of the 3 consecutive daily ON hours from the Hauser diary at each visit. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.

Time frame:
Weeks 3, 5, 10 and 15; Baseline was defined as the average daily ON time without Troublesome Dyskinesia (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit Day 0)
Reported as:
Least squares mean · Hours
Change From Baseline in Daily ON Time Without Troublesome Dyskinesia
HoursPlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
Change at Week 30.61 ± 0.5771.74 ± 1.173-0.49 ± 1.0471.93 ± 1.1280.77 ± 0.443
Change at Week 50.02 ± 0.5482.39 ± 1.1501.31 ± 1.0581.12 ± 1.0291.31 ± 0.436
Change at Week 100.61 ± 0.6180.92 ± 1.4130.45 ± 1.5982.64 ± 1.1941.65 ± 0.508
Change at Week 15-0.81 ± 1.0990.37 ± 2.999-4.48 ± 3.1920.94 ± 1.7811.50 ± 0.825
SecondaryChange From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III

MDS-UPDRS Part III assessed the motor signs of Parkinson's disease and was administered by the investigator. It was comprised of 33 sub-scores based on 18 items, several with right, left or other body distribution scores. Each question was anchored with 5 responses that were linked to commonly accepted clinical terms: 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. If more than 7 of the Part III items were missing, the score for that time point was missing, otherwise MDS-UPDRS Part III score was imputed as sum of the non-missing items\*(total number of items)/ (number of items non-missing). The MDS-UPDRS Part III total score range is 0-132. Higher score indicated more severe motor signs of Parkinson's disease. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.

Time frame:
Weeks 1, 2, 3, 4, 5, 10 and 15; Baseline was defined as the Day -1 (study derived day and equalled to nominal visit Day 0) measurement
Reported as:
Least squares mean · units on a scale
Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
units on a scalePlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
Change at Week 1-3.90 ± 2.054-4.44 ± 3.965-4.61 ± 3.593-1.90 ± 3.594-3.22 ± 1.524
Change at Week 2-0.95 ± 2.078-15.78 ± 6.252—0.56 ± 6.129-3.70 ± 1.584
Change at Week 3-3.80 ± 2.848-12.39 ± 8.240——-3.06 ± 2.069
Change at Week 4-6.28 ± 2.182-0.84 ± 3.940-2.48 ± 3.572-2.91 ± 3.575-6.05 ± 1.574
Change at Week 5-5.12 ± 2.386-6.14 ± 4.4143.10 ± 4.347-1.22 ± 3.935-4.86 ± 1.765
Change at Week 10-5.09 ± 1.967-2.21 ± 3.9025.77 ± 5.365-2.36 ± 3.607-9.32 ± 1.526
Change at Week 15-0.18 ± 3.1707.72 ± 8.6602.09 ± 9.495-5.44 ± 5.364-1.84 ± 2.519
SecondaryChange From Baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, IV, and Total Score

Each question of Part I,II or IV with 5 responses was linked to the same clinical terms as Part III.The score was missing if more than 7 items were missing for a time point; otherwise Part I,II or IV score was imputed as sum of non-missing items\*(total number of items)/(number of items non-missing).•PartI (Non-Motor Aspects of Experiences of Daily Living) assessed non-motor experiences of daily living using 13questions(Range:0-52).•PartII(Motor Aspects of Experiences of Daily Living) assessed motor experiences of daily living using 13questions(Range:0-52).•PartIV(Motor Complications) assessed motor complications,dyskinesias, and motor fluctuations using historical and objective information with 6questions(Range:0-24).•MDS-UPDRS Total Score:the sum of Parts I,II,III,and IV(Range:0-260).Higher score indicated more severe motor signs of Parkinson's disease.Week15's results were interpreted cautiously given almost half participants were not available for the analysis as compared to Week10

Time frame:
Weeks 5, 10 and 15; Baseline was defined as the Day -1 (study derived day and equalled to nominal visit Day 0) measurement
Reported as:
Mean · units on a scale
Change From Baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, IV, and Total Score
units on a scalePlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
Change at Week 5 (Part I Score)-0.75 ± 5.508-0.83 ± 1.9410.67 ± 4.8852.00 ± 4.4081.12 ± 4.879
Change at Week 10 (Part I Score)-0.69 ± 4.557-0.80 ± 2.168-1.00 ± 2.8280.00 ± 2.4490.17 ± 4.086
Change at Week 15 (Part I Score)-2.86 ± 6.1762.00 ± NA6.00 ± NA-1.00 ± 1.7321.00 ± 5.745
Change at Week 5 (Part II Score)0.06 ± 5.836-1.83 ± 2.6393.00 ± 4.940-0.03 ± 3.083-0.24 ± 4.068
Change at Week 10 (Part II Score)-0.35 ± 5.267-1.00 ± 1.2255.00 ± 1.4140.13 ± 2.428-0.43 ± 4.240
Change at Week 15 (Part II Score)-1.38 ± 4.7792.00 ± NA8.00 ± NA-2.42 ± 5.2701.47 ± 5.986
Change at Week 5 (Part IV Score)-1.50 ± 2.895-0.83 ± 2.401-0.50 ± 4.8480.25 ± 2.053-0.65 ± 2.806
Change at Week 10 (Part IV Score)-2.00 ± 2.3180.80 ± 1.304-3.00 ± 5.6570.00 ± 1.789-1.13 ± 3.530
Change at Week 15 (Part IV Score)-2.75 ± 2.493-2.00 ± NA-7.00 ± NA-1.33 ± 2.082-1.27 ± 2.404
Change at Week 5 (Total Score)-8.88 ± 12.832-10.00 ± 7.6165.33 ± 16.8602.34 ± 12.010-4.21 ± 18.216
Change at Week 10 (Total Score)-8.75 ± 10.951-3.60 ± 8.6496.50 ± 7.7780.13 ± 10.569-11.40 ± 18.448
Change at Week 15 (Total Score)-7.86 ± 12.4560.00 ± NA13.00 ± NA-9.08 ± 13.1350.73 ± 17.260
SecondaryNumber of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality

The safety laboratory tests including Hematology, Clinical Chemistry and Urinalysis were performed. Determination if there were any laboratory data abnormalities of potential clinical concern was based on Pfizer Data Standards. Incidence of laboratory test abnormalities (without regard to baseline abnormality) was summarized within each treatment group.

Time frame:
Baseline (Day 0) to Week 17
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
ParticipantsPlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality1949725
SecondaryNumber of Participants With Vital Sign Results Meeting the Criteria for Categorical Summarization

Vital Signs including blood pressure and pulse rate were measured. Vital signs were collected first while the participant was in the supine position and then in the standing position.

Time frame:
Baseline (Day 0) to Week 17
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Results Meeting the Criteria for Categorical Summarization
ParticipantsPlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
<90 mmHg (Supine Systolic Blood Pressure [SBP])11203
Max-Increase from Baseline >= 30 mmHg (Supine SBP)41213
Max-Decrease from Baseline >= 30 mmHg (Supine SBP)412211
<90 mmHg (Standing SBP)41327
Max-Increase from Baseline >=30mmHg (Standing SBP)40313
Max-Decrease from Baseline >=30mmHg (Standing SBP)303212
<50 mmHg (Supine Diastolic Blood Pressure [DBP])00011
Max-Increase from Baseline >=20 mmHg (Supine DBP)10013
Max-Decrease from Baseline >=20 mmHg (Supine DBP)102113
<50 mmHg (Standing DBP)20121
Max-Increase from Baseline >=20mmHg (Standing DBP)30201
Max-Decrease from Baseline >=20mmHg (Standing DBP)523217
<40 beats per minute (bpm) (Supine Pulse Rate)00000
>120 bpm (Supine Pulse Rate)00000
<40 bpm (Standing Pulse Rate)00000
>140 bpm (Standing Pulse Rate)00000
SecondaryNumber of Participants With Electrocardiogram (ECG) Results Meeting the Criteria for Categorical Summarization

The average of the triplicate readings of ECG data was collected at each assessment time. Number of participants with ECG results meeting the criteria for categorical summarization for time from the beginning of the P wave until the beginning of the QRS complex (PR Interval), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS Duration), time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT Interval) and corrected QT (Fridericia correction) (QTcF Interval) were presented.

Time frame:
Baseline (Day 0) to Week 17
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Results Meeting the Criteria for Categorical Summarization
ParticipantsPlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
>=300 msec (PR Interval)10000
Max-Increase From Baseline(%)>=25/50%(PR Interval)00000
>=140 msec (QRS Duration)00000
Max-Increase From Baseline(%)>=50% (QRS Duration)00000
>=500 msec (QT Interval)10000
450 - <480 msec (QTcF Interval)20001
480 - <500 msec (QTcF Interval)00000
>=500 msec (QTcF Interval)00000
Max-Increase From Baseline 30-<60 (QTcF Interval)10001
Max-Increase From Baseline >=60 (QTcF Interval)00000
SecondaryNumber of Participants With Suicidal Ideation Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS) at Post-baseline Visits

The Columbia Suicide Severity Rating Scale (C-SSRS) was an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS responses were mapped to the C-CASA. There were 3 key endpoints for suicidality data analysis and evaluation: * Suicidal Behavior: A participant was said to have suicidal behavior if the participant had experienced completed suicide / suicide attempt / reparatory acts toward imminent suicidal behavior. * Suicidal Ideation: Any observed suicidal ideation mapped to a single C-CASA category. * Suicidal Behavior or Ideation (participants with new onset suicidality): A participant was considered to have a new onset of suicidality if the participant reported no ideation and no behavior at the baseline assessment and reported any behavior or ideation post-baseline. Data observed at screening was not considered in the definition of worsening.

Time frame:
Days 0 (Baseline), 7, 14, 21, 28, 35, 70, 77, 84, 91, 105 and 119
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS) at Post-baseline Visits
ParticipantsPlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
Baseline10100
Day 700000
Day 1400001
Day 2100002
Day 2800000
Day 3500001
Day 7000000
Day 770———0
Day 840———0
Day 910———0
Day 10500010
Day 11900—00
SecondaryChange From Baseline in Total Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)

The QUIP-RS was a brief, patient reported outcome measure designed to assess the severity of symptoms of Impulsive-Compulsive Disorders (ICDs) and related behaviors reported to occur in Parkinson's disease. The QUIP-RS assessed 7 disorders (Gambling, Sex, Buying, Eating, Hobbyism-punding \[performing tasks and repeating activities\] and Taking medications). If more than 5 items were missing, the total QUIP-RS score was set as missing; otherwise, the total QUIP-RS score was imputed as follows: sum of the non-missing item scores \* (total number of items) / (number of items non-missing). The higher score indicated a greater level of the ICD. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112.

Time frame:
Baseline (Day 0) and Weeks 5, 10 and 15
Reported as:
Mean · units on a scale
Change From Baseline in Total Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)
units on a scalePlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
Baseline17.1 ± 16.989.0 ± 12.569.0 ± 14.3912.5 ± 11.696.8 ± 11.40
Change at Week 5-5.6 ± 11.372.3 ± 10.054.7 ± 9.58-5.4 ± 12.280.5 ± 11.13
Change at Week 10-3.3 ± 12.16-1.8 ± 7.98-6.5 ± 9.63-5.8 ± 13.501.0 ± 10.62
Change at Week 15-11.5 ± 16.293.0 ± 10.30-3.3 ± 5.77-17.0 ± 11.340.4 ± 5.91
SecondaryTotal Physician Withdrawal Checklist (PWC-20) on Days 105 and 119, and Change From Day 105 to Day 119

The PWC-20 is a physician completed, 20 item reliable and sensitive instrument for the assessment of discontinuation symptoms. The PWC-20 was collected after the completion of study treatment and also at the first visit of follow-up. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. If more than 5 items were missing, the total PWC-20 score was missing; otherwise, the total PWC-20 score was imputed as follows: sum of the non-missing items \* (total number of items) / (number of items non-missing). The higher score indicated more frequent/severe symptoms.

Time frame:
Days 105 and 119
Reported as:
Mean · units on a scale
Total Physician Withdrawal Checklist (PWC-20) on Days 105 and 119, and Change From Day 105 to Day 119
units on a scalePlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
Day 105 Early Termination (ET)3.5 ± 3.735.6 ± 5.685.8 ± 6.658.2 ± 8.787.1 ± 6.06
Day 119 Follow-up (FU)3.3 ± 3.086.0 ± NA—7.7 ± 4.165.8 ± 5.45
Change From Day 105 ET to Day 119 FU-0.6 ± 3.08-11.0 ± NA—-1.7 ± 4.73-0.4 ± 4.79
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths

An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event did not need necessarily to have a causal relationship with the treatment or usage. An SAE was any untoward medical occurrence at any dose that: * Resulted in death; * Was life threatening (immediate risk of death); * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); * Resulted in congenital anomaly/birth defect.

Time frame:
Day 1 to follow-up (Week 19 visit)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths
ParticipantsPlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
AEs207111037
SAEs11002
Discontinuation due to AEs31329
Death10001

Adverse events

Collected over Day 1 to follow-up (Week 19 visit). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/23 (4.3%)1/23 (4.3%)15/23 (65.2%)
PF-06649751 1 mg QD0/13 (0%)1/13 (7.7%)7/13 (53.8%)
PF-06649751 3 mg QD0/15 (0%)0/15 (0%)11/15 (73.3%)
PF-06649751 7 mg QD0/13 (0%)0/13 (0%)10/13 (76.9%)
PF-06649751 15 mg QD1/44 (2.3%)2/44 (4.5%)31/44 (70.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
NephrolithiasisRenal and urinary disorders0/231/130/150/130/44
UreterolithiasisRenal and urinary disorders0/231/130/150/130/44
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/230/130/150/130/44
Neck painMusculoskeletal and connective tissue disorders0/230/130/150/131/44
Pain in extremityMusculoskeletal and connective tissue disorders0/230/130/150/131/44
Dermatitis allergicSkin and subcutaneous tissue disorders0/230/130/150/131/44
Abdominal painGastrointestinal disorders0/230/130/150/131/44
Allergic oedemaImmune system disorders0/230/130/150/131/44
Most frequent other events
Showing 10 of 62
Most frequent other events
EventPlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QD
NauseaGastrointestinal disorders1/232/132/151/1311/44
HeadacheNervous system disorders0/232/131/153/1311/44
DyskinesiaNervous system disorders2/231/131/153/137/44
FatigueGeneral disorders3/231/132/152/131/44
ContusionInjury, poisoning and procedural complications0/231/130/152/130/44
FallInjury, poisoning and procedural complications2/232/131/152/132/44
DizzinessNervous system disorders0/230/131/152/134/44
HypotensionVascular disorders0/230/132/150/130/44
NasopharyngitisInfections and infestations3/230/130/150/130/44
InsomniaPsychiatric disorders3/231/130/151/132/44

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QDTotal
Mean66.04 ± 8.7966.92 ± 8.7963.80 ± 7.7667.77 ± 9.3663.41 ± 8.4764.97 ± 8.60
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QDTotal
Female66641840
Male177992668
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QDTotal
Hispanic or Latino3311311
Not Hispanic or Latino201013124095
Unknown or Not Reported001012
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboPF-06649751 1 mg QDPF-06649751 3 mg QDPF-06649751 7 mg QDPF-06649751 15 mg QDTotal
American Indian or Alaska Native000101
Asian1021610
Native Hawaiian or Other Pacific Islander000000
Black or African American210216
White20121293689
More than one race000000
Unknown or Not Reported001012
08

Study locations

57 sites
  • Xenoscience, Inc
    Phoenix, Arizona 85004, United States
  • St Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • Arcadia Neurology Center
    Arcadia, California 91006, United States
  • Faculty Physicians and Surgeons of Loma Linda University School of Medicine
    Loma Linda, California 92354, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92658, United States
  • Hoag Memorial Hospital
    Newport Beach, California 92663, United States
  • SC3 Research Group, Inc
    Pasadena, California 91105, United States
  • Neurosearch-Torrance
    Torrance, California 90505, United States
  • Associated Neurologists of Southern Connecticut, PC
    Fairfield, Connecticut 06824, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
  • University of Florida Center for Movement Disorders and Neurorestoration
    Gainesville, Florida 32607, United States
  • Neurology Associates of Ormond Beach
    Ormond Beach, Florida 32174, United States
  • University of South Florida
    Tampa, Florida 33613, United States
  • Vero Beach Neurology and Research Institute
    Vero Beach, Florida 32960, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Indiana University Health Neuroscience Center
    Indianapolis, Indiana 46202, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • CRI Worldwide, LLC
    Marlton, New Jersey 08053, United States
  • Dent Neurologic Institute
    Amherst, New York 14226, United States
  • Dent Neurosciences Research Center ,Inc. DBA Dent Neurologic Institute
    Amherst, New York 14226, United States
  • Dent Neurologic Institute
    Orchard Park, New York 14127, United States
  • Duke University Medical center
    Durham, North Carolina 27705, United States
  • Duke University/Duke Neurology/Department of Neurology
    Durham, North Carolina 27705, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • The Movement Disorder Clinic of Oklahoma
    Tulsa, Oklahoma 74136, United States
  • Abington Neurological Associates, Ltd.
    Willow Grove, Pennsylvania 19090, United States
  • Rhode Island Hospital/ Brown University Medical School
    Providence, Rhode Island 02903, United States
  • AS Clinical Research Consultants of North Texas, PLLC
    Greenville, Texas 75401, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Booth Gardner Parkinson's Care Center
    Kirkland, Washington 98034, United States
  • Montreal Neurological Hospital Research Pharmacy
    Montreal, Quebec H3A 2B4, Canada
  • Montreal Neurological Institute and Hospital
    Montreal, Quebec H3A 2B4, Canada
  • CHU de Grenoble Alpes
    Grenoble, 38043 Cedex 9, France
  • CHU de Grenoble Alpes
    La Tronche, 38700, France
  • CHRU de Lille-Hopital Roger Salengro
    Lille, 59037 cedex, France
  • Hopital de la Timone APHM
    Marseille, 13385 cedex 05, France
  • Hopital de La Timone
    Marseille, 13385 cedex 05, France
  • Hopital La Pitie-Salpetriere
    Paris, 75013, France
  • Universitaetsklinikum Freiburg
    Freiburg, Baden-wuerttemberg 79106, Germany
  • St. Josef-Hospital GmbH
    Bochum, 44791, Germany
  • Universitaetsklinikum Carl Gustav Carus Klinik und Poliklinik fur Neurologie
    Dresden, 01307, Germany
  • Klinikum rechts der Isar der Technischen Universitaet Muenchen
    Muenchen, 81675, Germany
  • Universitaetsklinik Ulm
    Ulm, 89081, Germany
  • Asahikawa Medical center
    Asahikawa, Hokkaido 0708644, Japan
  • Medical Corporation Abe Neurology Clinic
    Morioka, Iwate 020-0878, Japan
  • Tazuke Kofukai Medical Research Institute Kitano Hospital
    Kita-ku, Osaka 530-8480, Japan
  • Osaka University Hospital
    Suita, Osaka 565-0871, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
  • Hospital Clinico Universitario
    Santiago de Compostela, A Coruna 15706, Spain
  • Hospital Universitari de Bellvitge
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Policlinica de Guipuzcoa
    San Sebastian, Guipuzcoa 20009, Spain
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario de la Princesa
    Madrid, 28006, Spain
  • Hospital Universitario y Politecnico la Fe
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Nov 2017, 20 months.

Results were first posted in Dec 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2016
First posted
Feb 22, 2016
StartActual
Mar 3, 2016
Primary completionActual
Nov 10, 2017
CompletionActual
Nov 10, 2017
Results first posted
Dec 24, 2018
Last update
Nov 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02687542
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 22, 2016
Start date
Mar 3, 2016
Primary completion
Nov 10, 2017
Completion
Nov 10, 2017
Results posted
Dec 24, 2018
Last update
Nov 23, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion